A Study of MK0431 in Patients With Type 2 Diabetes (0431-010)

Phase 2

Completed

• Conditions: Diabetes Mellitus, Type II

• Registration Number: NCT00482079
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

A dose-ranging study of MK0431 in patients with type 2 diabetes who have inadequate control of their blood sugar.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2003-05-13
• Primary Completion: 2004-08-25
• Study Completion: 2006-06-15
• Study First Submitted: 2007-06-01
• Study First Submitted QC: 2007-06-01
• Study First Posted: 2007-06-04
• Status Verified: 2017-03
• Last Update Submitted: 2017-03-24
• Last Update Posted: 2017-03-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 743

Inclusion Criteria

• Age 21 to 70, You are a man or non-pregnant woman

Read More

Exclusion Criteria

• Have a history of type I diabetes
• You are on a weight loss program with ongoing weight loss or taking weight loss medications
• You have a history of minor surgery
• You have received investigational drugs within 8 weeks of study start
• You have hepatitis B or C

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To asses the effectiveness of MK0431 compared to placebo	over 12 weeks

Secondary Outcome Measures

Name	Time	Method
To test the safety and tolerability of MK0431 in patients with type 2 diabetes